{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:42:26Z","timestamp":1790660546261,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T00:00:00Z","timestamp":1614902400000},"content-version":"am","delay-in-days":338,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100013733","name":"Ipsen Biopharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013733","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007054","name":"Meso Scale Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.ejca.2020.02.001","type":"journal-article","created":{"date-parts":[[2020,3,5]],"date-time":"2020-03-05T18:57:39Z","timestamp":1583434659000},"page":"107-116","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"special_numbering":"C","title":["Axitinib in first-line for patients with metastatic papillary renal cell carcinoma: Results of the multicentre, open-label, single-arm, phase II AXIPAP trial"],"prefix":"10.1016","volume":"129","author":[{"given":"Sylvie","family":"Negrier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Rioux-Leclercq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Ferlay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marine","family":"Gross-Goupil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwena\u00eblle","family":"Gravis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel","family":"Geoffrois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Chevreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Boyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Rolland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Blanc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Ravaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Slimane","family":"Dermeche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aude","family":"Flechon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Albiges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"P\u00e9rol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Escudier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ejca.2020.02.001_bib1","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1002\/cam4.1048","article-title":"Characterizing the outcomes of metastatic papillary renal cell carcinoma","volume":"6","author":"Connor","year":"2017","journal-title":"Cancer Med"},{"issue":"2","key":"10.1016\/j.ejca.2020.02.001_bib2","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1056\/NEJMoa1505917","article-title":"Comprehensive molecular characterization of papillary renal-cell carcinoma","volume":"374","author":"Linehan","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ejca.2020.02.001_bib3","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.celrep.2018.03.075","article-title":"The cancer genome atlas comprehensive molecular characterization of renal cell carcinoma","volume":"23","author":"Ricketts","year":"2018","journal-title":"Cell Rep"},{"issue":"13","key":"10.1016\/j.ejca.2020.02.001_bib4","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.1158\/1078-0432.CCR-13-2173","article-title":"MET is a potential target across all papillary renal cell carcinomas: result from a large molecular study of pRCC with CGH array and matching gene expression array","volume":"20","author":"Albiges","year":"2014","journal-title":"Clin Canc Res"},{"issue":"5","key":"10.1016\/j.ejca.2020.02.001_bib5","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/annonc\/mdz056","article-title":"Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Escudier","year":"2019","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2020.02.001_bib6","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1093\/annonc\/mdv149","article-title":"First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG)","volume":"26","author":"Ravaud","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2020.02.001_bib7","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ejca.2016.08.004","article-title":"Open-label phase 2 trial of first-line everolimus monotherapy in patients with papillary metastatic renal cell carcinoma: RAPTOR final analysis","volume":"69","author":"Escudier","year":"2016","journal-title":"Eur J Canc"},{"issue":"2","key":"10.1016\/j.ejca.2020.02.001_bib8","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1200\/JCO.2012.43.3383","article-title":"Phase II and biomarker study of the dual MET\/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma","volume":"31","author":"Choueiri","year":"2013","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1016\/j.ejca.2020.02.001_bib9","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1200\/JCO.2017.72.2967","article-title":"Biomarker-based phase II trial of savolitinib in patients with advanced papillary renal cell cancer","volume":"35","author":"Choueiri","year":"2017","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2020.02.001_bib10","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Canc"},{"issue":"3","key":"10.1016\/j.ejca.2020.02.001_bib11","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1200\/JCO.2004.06.132","article-title":"Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma","volume":"22","author":"Motzer","year":"2004","journal-title":"J Clin Oncol"},{"issue":"34","key":"10.1016\/j.ejca.2020.02.001_bib12","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.1200\/JCO.2008.21.4809","article-title":"Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study","volume":"27","author":"Heng","year":"2009","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2020.02.001_bib13","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1470-2045(12)70559-4","article-title":"External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study","volume":"14","author":"Heng","year":"2013","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2020.02.001_bib14","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1093\/annonc\/mdr586","article-title":"Multicenter phase II study of sunitinib in patients with non-clear cell renal cell carcinoma","volume":"23","author":"Lee","year":"2012","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2020.02.001_bib15","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.eururo.2012.06.043","article-title":"A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma","volume":"62","author":"Tannir","year":"2012","journal-title":"Eur Urol"},{"issue":"34","key":"10.1016\/j.ejca.2020.02.001_bib16","doi-asserted-by":"crossref","first-page":"5788","DOI":"10.1200\/JCO.2008.18.8821","article-title":"Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317","volume":"27","author":"Gordon","year":"2009","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2020.02.001_bib17","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/S1470-2045(15)00515-X","article-title":"Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial","volume":"17","author":"Armstrong","year":"2016","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2020.02.001_bib18","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.eururo.2015.10.049","article-title":"Everolimus versus sunitinib prospective evaluation in metastatic non-clear cell renal cell carcinoma (ESPN): a randomized multicenter phase 2 trial","volume":"69","author":"Tannir","year":"2016","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.ejca.2020.02.001_bib19","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3233\/KCA-170018","article-title":"Parallel (randomized) phase II evaluation of tivantinib (ARQ197) and tivantinib in combination with erlotinib in papillary renal cell carcinoma: SWOG S1107","volume":"1","author":"Twardowski","year":"2017","journal-title":"Kidney Cancer"},{"key":"10.1016\/j.ejca.2020.02.001_bib20","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ejca.2017.10.014","article-title":"Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial","volume":"87","author":"Schoffski","year":"2017","journal-title":"Eur J Canc"},{"issue":"5","key":"10.1016\/j.ejca.2020.02.001_bib21","doi-asserted-by":"crossref","first-page":"v381","DOI":"10.1093\/annonc\/mdz249.044","article-title":"First-line pembrolizumab (pembro) monotherapy for advanced non-clear cell renal cell carcinomab (nccRCC): Updated follow-up for KEYNOTE-427 cohort B","volume":"30","author":"Suarez","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2020.02.001_bib22","series-title":"Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and\/or Sarcomatoid Features.","first-page":"63","volume":"Jan 38(1)","author":"McKay","year":"2020"},{"key":"10.1016\/j.ejca.2020.02.001_bib23","series-title":"Overall survival results of durvalumab and savolitinib in metastatic papillary renal cancer (CALYPSO)","volume":"38","author":"Suarez-Rodriguez","year":"2020"},{"issue":"5","key":"10.1016\/j.ejca.2020.02.001_bib24","first-page":"e997","article-title":"A multicenter phase II trial of axitinib in patients with recurrent or metastatic non-clear-cell renal cell carcinoma who had failed prior treatment with temsirolimus","volume":"16","author":"Park","year":"2018","journal-title":"Clin Genitourin Canc"},{"issue":"12","key":"10.1016\/j.ejca.2020.02.001_bib25","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1097\/PAS.0000000000000962","article-title":"Toward biological subtyping of papillary renal cell carcinoma with clinical implications through histologic, immunohistochemical, and molecular analysis","volume":"41","author":"Saleeb","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ejca.2020.02.001_bib26","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ejca.2018.08.014","article-title":"Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: a retrospective analysis","volume":"104","author":"Campbell","year":"2018","journal-title":"Eur J Canc"},{"issue":"4","key":"10.1016\/j.ejca.2020.02.001_bib27","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S1470-2045(18)30907-0","article-title":"Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study","volume":"20","author":"Martinez","year":"2019","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2020.02.001_bib28","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s41591-018-0053-3","article-title":"Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma","volume":"24","author":"McDermott","year":"2018","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.ejca.2020.02.001_bib29","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.ejca.2020.02.001_bib30","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"N Engl J Med"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804920300253?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804920300253?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:27:02Z","timestamp":1760732822000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804920300253"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":30,"alternative-id":["S0959804920300253"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2020.02.001","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Axitinib in first-line for patients with metastatic papillary renal cell carcinoma: Results of the multicentre, open-label, single-arm, phase II AXIPAP trial","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2020.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}